efavirenz has been researched along with Central Nervous System Disease in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Feng, W; Li, X; Sun, F; Wang, Y; Weng, B; Xia, P; Yuan, Q | 1 |
| Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS | 1 |
| Castro, L; Chow, DC; Duerler, T; Gangcuangco, LMA; Kallianpur, KJ; Kohorn, L; Nagamine, L; Nakamoto, BK; Paul, R; Pien, FD; Shikuma, CM; Soll, B; Souza, S; Walker, M | 1 |
| Akhondzadeh, S; Alimadadi, A; Dabaghzadeh, F; Ghaeli, P; Jafari, S; Khalili, H; Khazaeipour, Z | 1 |
| Cabrera Figueroa, S; Carracedo Álvarez, A; Cruz Guerrero, R; Hurlé, AD; Hurtado, LP; Sánchez Martín, A | 1 |
| Abrams, EJ; Tsague, L | 1 |
| Andrieux-Meyer, I; Calmy, A; Ford, N; Mofenson, L; Renaud, F; Shaffer, N; Shubber, Z; Vitoria, M | 1 |
| Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M | 1 |
| Alvarez, A; Apostolova, N; Blas-Garcia, A; Esplugues, JV; Funes, HA; Galindo, MJ | 1 |
| Currán, A; Deig, E; Guardiola, JM; Guelar, A; Llibre, JM; Martínez-Madrid, O; Pedrol, E; Ramírez, R; Tasias, M; Tikhomirova, L | 1 |
| Baker, P; Chirwa, S; Erdem, H; Haas, DW; Leger, P; Leonard, M; Olson, L; Richardson, DM; Turner, M | 1 |
| Burger, DM; de Mast, Q; Homberg, JR; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Chêne, G; Gallien, S; Journot, V; Loriot, MA; Molina, JM; Morlat, P; Reliquet, V; Reynes, J; Sauvageon, H | 1 |
| Bentley, TGK; Broder, MS; Chang, E; Myers, J; Papoyan, E; Reddy, SR; Rosenblatt, L | 1 |
| Roca, B | 1 |
| Carey, D; Emery, S; Goodall, R; Hudson, F; Mallon, P; Mijch, A; Read, TR; Wand, H | 1 |
| Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A | 1 |
| Arribas, JR | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 1 |
| Acosta, EP; Clifford, DB; Gulick, RM; Haas, DW; Hulgan, T; Kim, RB; Marzolini, C; Ribaudo, HJ; Tierney, C; Wilkinson, GR | 1 |
| Burger, D; Clotet, B; Ferrer, MJ; Fumaz, CR; Gómez, G; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pérez-Alvarez, N; Sirera, G | 1 |
| Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F | 1 |
| Antolini, D; Concia, E; Faggian, F; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Antón, R; Borrás, J; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S | 1 |
| Acosta, EP; Clifford, DB; Dorfman, D; Evans, S; Goodkin, K; Gulick, RM; Ribaudo, H; Simpson, D; Tashima, K; Yang, Y | 1 |
| Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR | 1 |
| Colebunders, R; Verdonck, K | 1 |
| Bonjoch, A; Clotet, B; Ferrer, MJ; Fumaz, CR; Jou, T; Negredo, E; Paredes, R; Romeu, J; Sirera, G; Tuldrà, A; Tural, C | 1 |
7 review(s) available for efavirenz and Central Nervous System Disease
| Article | Year |
|---|---|
Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Treatment Outcome; Viral Load | 2020 |
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Reverse Transcriptase Inhibitors; Treatment Outcome | 2014 |
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans | 2015 |
Efavirenz and the CNS: what we already know and questions that need to be answered.
Topics: Alkynes; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Central Nervous System; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; HIV Infections; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2015 |
Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.
Topics: Africa; Alkynes; Benzoxazines; Central Nervous System Diseases; Child; Cognition; Cyclopropanes; HIV Infections; HIV-1; Humans; Odds Ratio; Reverse Transcriptase Inhibitors | 2016 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir | 2008 |
Efavirenz: enhancing the gold standard.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; HIV Infections; Humans; Oxazines; Patient Compliance | 2003 |
9 trial(s) available for efavirenz and Central Nervous System Disease
| Article | Year |
|---|---|
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; Genomics; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Neurotransmitter Transport Proteins; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Neurotransmitter; Reverse Transcriptase Inhibitors | 2018 |
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cyproheptadine; Depression; Double-Blind Method; Female; HIV Infections; Humans; Iran; Male; Mental Disorders; Personality Inventory; Psychiatric Status Rating Scales; Serotonin Antagonists; Socioeconomic Factors; Suicidal Ideation; Surveys and Questionnaires; Treatment Outcome | 2013 |
Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Genetic Predisposition to Disease; HIV Infections; Humans; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide | 2017 |
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Feasibility Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viral Load | 2011 |
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Female; Follow-Up Studies; Gynecomastia; HIV Infections; Humans; Hypersensitivity; Liver Diseases; Male; Metabolic Diseases; Nevirapine; Oxazines; Pancreatic Diseases; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cohort Studies; Cyclopropanes; Cytochrome P-450 Enzyme System; Double-Blind Method; Female; Humans; Male; Oxazines; Pharmacogenetics; Polymorphism, Genetic | 2004 |
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Oxazines; Risk Factors | 2005 |
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Mood Disorders; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Sleep Wake Disorders | 2005 |
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Therapy, Combination; Emotions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Patient Compliance; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2002 |
16 other study(ies) available for efavirenz and Central Nervous System Disease
| Article | Year |
|---|---|
Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cobicistat; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Sleep Wake Disorders; Tenofovir | 2018 |
Impact of pharmacogenetics on CNS side effects related to efavirenz.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers, Pharmacological; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Commentary: Antiretroviral treatment for pregnant and breastfeeding women--the shifting paradigm.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2014 |
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Drug Substitution; Female; HIV Infections; Humans; Male; Medication Adherence; Mental Disorders; Middle Aged; Nevirapine; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors | 2015 |
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
Topics: Adult; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Ethnicity; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Steroid Hydroxylases; Withholding Treatment | 2016 |
Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.
Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2017 |
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; HIV Infections; Humans; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sleep Initiation and Maintenance Disorders | 2009 |
Safe substitution for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans; Hyperlipidemias; Nevirapine; Oxazines; Patient Selection; Retrospective Studies; Treatment Outcome; Viral Load | 2004 |
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cognition Disorders; Cyclopropanes; Employment; Female; Humans; Male; Mood Disorders; Oxazines; Patient Compliance; Quality of Life; Retrospective Studies; Risk-Taking; Surveys and Questionnaires | 2005 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exanthema; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nevirapine; Odds Ratio; Oxazines | 2005 |
Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Retrospective Studies; Substance-Related Disorders | 2005 |
Summaries for patients. Neuropsychological side effects of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Mood Disorders; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Sleep Wake Disorders | 2005 |
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones | 2006 |
No increase in CNS defects.
Topics: Alkynes; Anti-HIV Agents; Baltimore; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Dandy-Walker Syndrome; Female; HIV Infections; Humans; Infant, Newborn; Medical Staff, Hospital; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2006 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Dideoxynucleosides; Dizziness; Drug Therapy, Combination; Headache; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1999 |